Friedreich's Ataxia News and Research

RSS
Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous system resulting in symptoms ranging from gait disturbance and speech problems to heart disease. A well-known celebrity afflicted with Friedreich's ataxia is former major leaguer and noted historian Clinton Stewart.
Edison's EPI-743 receives FDA orphan drug designation for treatment of Leigh syndrome

Edison's EPI-743 receives FDA orphan drug designation for treatment of Leigh syndrome

Research suggests that person can slow aging process by exercising regularly

Research suggests that person can slow aging process by exercising regularly

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

FDA grants Fast Track designation to Edison’s lead drug EPI-743

FDA grants Fast Track designation to Edison’s lead drug EPI-743

Edison Pharmaceuticals initiates Phase 2B/3 study of EPI-743 in children with Leigh syndrome

Edison Pharmaceuticals initiates Phase 2B/3 study of EPI-743 in children with Leigh syndrome

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

Longtime allies team up to create Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

UMMS launches Voyager Therapeutics to develop life-changing treatments for fatal diseases

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

Edison's vatiquinone receives Orphan Status for treatment of Friedreich's ataxia

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

FARA funds gene therapy-based research project to tackle Friedreich's ataxia

Scientists join patients to address Friedreich's Ataxia

Scientists join patients to address Friedreich's Ataxia

Viropharma announces financial results for third quarter 2013

Viropharma announces financial results for third quarter 2013

Viropharma announces financial results for second quarter of 2013

Viropharma announces financial results for second quarter of 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Friedreich's Ataxia costs between £11,000 and £19,000 per person per year

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Edison Pharmaceuticals to commence EPI-743 phase 2B Friedreich's ataxia study

Study discovers pathways that govern instability of GAA/TTC repeats

Study discovers pathways that govern instability of GAA/TTC repeats

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma initiates maribavir Phase 2 program for CMV infections

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline